DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients

2008 ◽  
Vol 124 (11) ◽  
pp. 2677-2682 ◽  
Author(s):  
Yasuhito Yuasa ◽  
Hiromi Nagasaki ◽  
Yoshimitsu Akiyama ◽  
Yutaka Hashimoto ◽  
Touichirou Takizawa ◽  
...  
Keyword(s):  
Physical Activity ◽  
Gastric Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Green Tea ◽  
Methylation Status ◽  
Gastric Cancer Patients

scholarly journals DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defect

2009 ◽  
Vol 124 (10) ◽  
pp. 2367-2374 ◽  
Author(s):  
Takayuki Ando ◽  
Takeichi Yoshida ◽  
Shotaro Enomoto ◽  
Kiyoshi Asada ◽  
Masae Tatematsu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Gastric Cancer Patients ◽  
Microrna Genes ◽  
Field Defect

Methylation status of IGF2 DMR and LINE1 in leukocyte DNA provides distinct clinicopathological features of gastric cancer patients

2017 ◽  
Vol 18 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Tomomitsu Tahara ◽  
Sayumi Tahara ◽  
Noriyuki Horiguchi ◽  
Tomohiko Kawamura ◽  
Masaaki Okubo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Methylation Status ◽  
Clinicopathological Features ◽  
Igf2 Dmr ◽  
Gastric Cancer Patients

scholarly journals Methylomic analysis identifies C11orf87 as a novel epigenetic biomarker for GI cancers

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250499
Author(s):  
Mita T. M. T. Tran ◽  
Kun-Tu Yeh ◽  
Yu-Ming Chuang ◽  
Po-Yen Hsu ◽  
Jie-Ting Low ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Cancer Cell ◽  
Gastric Cancer Cell ◽  
Ectopic Expression ◽  
Gastric Cancer Cell Line ◽  
Cancer Cell Line ◽  
Gi Cancers ◽  
Gastric Cancer Patients

Gastric cancer is one of the leading causes of cancer death worldwide. Previous studies demonstrated that activation of STAT3 is crucial for the development and progression of gastric cancer. However, the role of STAT3 in neuronal related gene methylation in gastric cancer has never been explored. In this study, by using DNA methylation microarray, we identified a potential STAT3 target, C11orf87, showing promoter hypomethylation in gastric cancer patients with lower STAT3 activation and AGS gastric cancer cell lines depleted with STAT3 activation. Although C11orf87 methylation is independent of its expression, ectopic expression of a constitutive activated STAT3 mutant upregulated its expression in gastric cancer cell line. Further bisulfite pyrosequencing demonstrated a progressive increase in DNA methylation of this target in patient tissues from gastritis, intestinal metaplasia, to gastric cancer. Intriguingly, patients with higher C11orf87 methylation was associated with better survival. Furthermore, hypermethylation of C11orf87 was also frequently observed in other GI cancers, as compared to their adjacent normal tissues. These results suggested that C11orf87 methylation may serve as a biomarker for diagnosis and prognosis of GI cancers, including gastric cancer. We further postulated that constitutive activation of STAT3 might be able to epigenetically silence C11orf87 as a possible negative feedback mechanism to protect the cells from the overactivation of STAT3. Targeted inhibition of STAT3 may not be appropriate in gastric cancer patients with promoter hypermethylation of C11orf87.

scholarly journals Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer

2018 ◽  
Vol 28 (2) ◽  
Author(s):  
Amin Abbasi ◽  
Sahar Heydari
Keyword(s):  
Gastric Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Methylation Status ◽  
Blood Samples ◽  
Specific Pcr ◽  
Expression Rate ◽  
And Performance ◽  
Gastric Cancer Patients ◽  
Gene Age

As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer.

scholarly journals Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients

2021 ◽  
Vol 20 ◽  
pp. 153303382097327
Author(s):  
Evangelos I. Karamitrousis ◽  
Ioanna Balgkouranidou ◽  
Nikolaos Xenidis ◽  
Kyriakos Amarantidis ◽  
Eirini Biziota ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Methylation Status ◽  
Progression Free Survival ◽  
Cell Free Dna ◽  
Free Survival ◽  
Free Dna ◽  
Gastric Cancer Patients

Epigenetic modification of several genes is a key component in the development of gastric cancer. The methylation status of RASSF1A, SOX17 and Wif-1 genes was evaluated in the cell free circulating DNA of 70 patients with advanced gastric cancer, using methylation-specific PCR. Patients with higher cell-free DNA concentration seem to have lower PFS, than patients with lower cell-free DNA concentration (p = 0.001). RASSF1A was the tumor suppressor gene, most frequently methylated in metastatic gastric cancer patients, followed by SOX17 and Wif-1 (74.3%, 60.0% and 47.1%, respectively). Patients having the SOX17 promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p < 0.001). Patients having the Wif-1 promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p = 0.001). Patients having the RASSF1A promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p = 0.004). Promoter methylation of the examined genes was significantly associated with a decrease in progression free survival and overall survival, comparing to that of patients without methylation. Simultaneous methylation of the above genes was associated with even worse progression free survival and overall survival. The methylation of RASSF1A, SOX-17 and Wif-1 and genes, is a frequent epigenetic event in patients with advanced gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document